Onxeo to host a Conference Call today to comment on the main findings from ReLive Phase III Study of Livatag®

Paris (France), September 18, 2017 – 8:00 am CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or the “Company”), a clinical-stage biotechnology company specializing in the development of innovative drugs for the treatment of orphan diseases, in particular in oncology, will host a conference call today for its shareholders at 3.00 pm CEST to comment on the main data from the ReLive Phase III Study of Livatag®.

This presentation will set out the main study data presented at the 11th Annual Conference of the International Liver Cancer Association in Seoul, South Korea (ILCA – 15-17 September 2017).


Conference call on September 18, 2017 at 3.00 pm CEST

Dial: +33 (0)1 72 00 15 10

Participant code: 92479704#

The call will be held in French

Speakers will include Judith Greciet, CEO of Onxeo, and Olivier de Beaumont, CMO.

The presentation will be available on the Company website, www.onxeo.com, in the Products section, prior to the call.